European Commission Expands Bavarian Nordic’s Mpox/Smallpox Vaccine Approval to Younger Children
Event summary
- European Commission approved Bavarian Nordic’s MVA-BN vaccine for children aged 2 to less than 12 years.
- Approval based on Phase 2 study with 227 children and 224 adults, showing non-inferior immune responses.
- Vaccine now authorized in the EU for individuals aged 2 years and older.
- Study co-funded by Coalition for Epidemic Preparedness Innovations (CEPI).
The big picture
This approval strengthens Bavarian Nordic’s position as a key player in global public health preparedness, particularly in regions like Africa where children have been disproportionately affected by mpox outbreaks. The expansion of MVA-BN’s authorization to younger age groups aligns with broader industry trends toward broadening vaccine accessibility and addressing vulnerable populations.
What we're watching
- Market Expansion
- How Bavarian Nordic will leverage this approval to increase market penetration in pediatric populations.
- Regulatory Momentum
- Whether other regions will follow with similar age-group expansions for MVA-BN.
- Competitive Positioning
- The pace at which Bavarian Nordic can solidify its leadership in mpox and smallpox vaccines amid global health threats.
Related topics